New European Moditope patent allowed for grant

RNS Number : 9734T

Scancell Holdings Plc

20 November 2019

 

20 November 2019

Scancell Holdings plc

("Scancell" or the "Company")

New European Moditope® patent allowed for grant;

Scancell to present at the NeoAg Summit in Boston

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, notes that the European Patent Office has announced its intention to grant Scancell's application for a European patent for its modified enolase peptides.

This patent will add to the protection of the Company's pipeline of Moditope® vaccines for the treatment of cancer. Commercial exclusivity will be provided in all major European territories such as: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey. 

Additionally, Scancell will be presenting at the NeoAg Summit being held at The Colonnade Hotel, 120 Huntingdon Avenue, Boston, MA from 20-22 November 2019. The conference is being held to address "Personalised Neo-antigen based Cancer Vaccines and Immunotherapies".

Professor Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy at the University of Nottingham, has been invited to give a presentation on 22 November entitled: "Citrullination - a widely expressed, novel, stress induced post-translational modification that is a potent target for cancer vaccines." The presentation will be focused on the discovery of the Moditope® platform and its translation into an immunotherapy with clinical utility for patients with solid tumours.

Cliff Holloway, Chief Executive Officer of Scancell, commented:

"The utility of the Moditope® technology is increasingly being recognised as a novel and important immunotherapeutic approach in the treatment of cancer, as evidenced by the expansion of our patent portfolio and selection for presentation on the international stage."

For Further Information:

Scancell Holdings plc
Dr John Chiplin, Chairman		[phone]
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl		[phone]
FTI Consulting Simon Conway/Natalie Garland-Collins		[phone]

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·      SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·      SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For further details, please see our website:  www.scancell.co.uk

 

END

 

 

MSCUKUKRKSAAAAA